Skip to main content

Table 3 AD neuropahological changes in sCJD and gCJD

From: The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins

 

sCJD

gCJDa

p

sCJDMM(V)1

V210I

p

E200Kb

pc

ABC score

 Not

144 (37.3)

29 (45.3)

0.481

93 (34.4)

9 (30.0)

0.747

11 (55.0)

0.170

 Low

210 (54.4)

30 (46.9)

152 (56.3)

17 (56.7)

8 (40.0)

 Intermediate/High

32 (8.3)

5 (7.8)

25 (9.3)

4 (13.3)

1 (5.0)

Thal score

 0

144 (37.3)

29 (45.3)

0.577

93 (34.4)

9 (30.0)

0.835

11 (55.0)

0.256

 1–2

118 (30.6)

15 (23.4)

84 (31.1)

8 (26.7)

4 (20.0)

 3

76 (19.7)

13 (20.3)

56 (20.7)

8 (26.7)

4 (20.0)

 4–5

48 (12.4)

7 (10.9)

37 (13.7)

5 (16.7)

1 (5.0)

CAA

 Not CAA

275 (71.2)

47 (73.4)

0.422

187 (69.3)

22 (73.3)

0.409

15 (75.0)

0.398

 CAA

111 (28.8)

17 (26.6)

83 (30.7)

8 (26.7)

5 (25.0)

Braak score

 0 − +

208 (53.9)

34 (53.1)

0.562

133 (49.3)

11 (36.7)

0.377

13 (65.0)

0.328

 I-II

133 (34.5)

25 (39.1)

102 (37.8)

15 (50.0)

6 (30.0)

 > III

45 (11.7)

5 (7.8)

35 (13.0)

4 (13.3)

1 (5.0)

 n

386

64

270

30

20

Age at death (years)

68.6 ± 8.9

65.0 ± 9.4

69.6 ± 8.3

65.9 ± 8.6

63.0 ± 9.1

  1. aGenetic CJD cases include the following mutations: 30 V210I, 22 E200K, 4 R208H, 2 E219K, 2 V203I, 2 INS (4 repeats), 1 INS (5 repeats), 1 D178N
  2. bTwo gCJDE200K-129 V showing PrPSc type 2 were excluded
  3. cPearson’s chi-square test was performed in comparison to sCJDMM(V)1 group